



ASX ANNOUNCEMENT

29 November 2018

Results from 2018 Annual General Meeting

Melbourne, Australia; 29 November 2018: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”) advises that the 2018 Annual General Meeting of shareholders was held at 10.30 am today (Melbourne time).

In accordance with Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001(Cth)*, details of the proxies received in respect of each resolution put to shareholders are set out in **Table 1** to this announcement. All resolutions that were put before the shareholders were passed on a show of hands.

FOR FURTHER INFORMATION PLEASE CONTACT

Dr Paul Kasian
Chairman and Interim CEO
Genetic Technologies Limited
+ 61 3 8412 7000

Jason Wong (USA)
Blueprint Life Science Group
+1 (415) 375 3340, Ext. 4

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company embracing blockchain technologies across Genomic testing platforms. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGen^{plus}[®], is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visit www.brevagenplus.com and www.phenogencesciences.com.

Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the [Private Securities Litigation Reform Act](#). The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.

Table 1 - Proxy results for 29 November 2018 Annual General Meeting

Description of Resolution	Manner in which the securityholder directed the proxy vote				
	For	Against	Discretionary Chairman *	Discretionary Other	Abstain
Consideration of Financial Statements	No Vote Required				
1. Adoption of the remuneration report Number of votes received Percentage of votes cast	178,398,195 89.7%	16,350,754 8.2%	3,228,194 1.6%	1,062,000 0.5%	1,604,888
2. Re-election of Dr Lindsay Wakefield as a Director Numbers of votes received Percentage of votes cast	192,965,142 84.1%	10,770,125 4.7%	24,431,938 10.7%	1,062,000 0.5%	643,333
3. Adoption of employee option plan Numbers of votes received Percentage of votes cast	190,053,435 82.9%	12,758,580 5.6%	25,216,608 11.0%	1,062,000 0.5%	781,915
4. The issue of performance rights to Dr Paul Kasian Numbers of votes received Percentage of votes cast	155,696,317 67.8%	48,499,893 21.1%	24,240,938 10.6%	1,062,000 0.5%	373,390
5. The issue of performance rights to Dr Lindsay Wakefield Numbers of votes received Percentage of votes cast	147,370,304 66.6%	48,560,643 22.0%	24,180,938 10.9%	1,062,000 0.5%	373,390
6. The issue of performance rights to Dr George Muchnicki Numbers of votes received Percentage of votes cast	155,469,368 74.6%	48,559,893 23.3%	3,341,250 1.6%	1,062,000 0.5%	536,783
7. The issue of performance rights to Mr Peter Rubinstein Numbers of votes received Percentage of votes cast	155,524,174 67.8%	48,560,643 21.2%	24,180,938 10.5%	1,062,000 0.5%	544,783

Description of Resolution (cont.)	Manner in which the securityholder directed the proxy vote				
	For	Against	Discretionary Chairman *	Discretionary Other	Abstain
8. The issue of performance rights to Mr Sam Lee Numbers of votes received Percentage of votes cast	155,589,067 67.8%	48,313,643 21.1%	24,434,438 10.6%	1,062,000 0.5%	473,390
9. Approval of issues under the standby equity placement facility (Kentgrove Capital Growth Fund) Numbers of votes received Percentage of votes cast	82,207,752 65.9%	17,356,086 13.9%	24,221,108 19.4%	1,062,000 0.8%	907,497
10. Ratification of issues under the standby equity placement facility (Kentgrove Capital Growth Fund) Numbers of votes received Percentage of votes cast	82,808,828 66.3%	16,755,010 13.4%	24,221,108 19.4%	1,062,000 0.9%	907,497
11. Strategic Alliance and issue of milestone shares to Blockchain Global Limited Numbers of votes received Percentage of votes cast	188,011,750 90.2%	16,098,020 7.7%	3,282,194 1.6%	1,062,000 0.5%	515,330
12. Approval of proposed new placement of shares to sophisticated investors Numbers of votes received Percentage of votes cast	183,271,433 80.2%	19,784,742 8.7%	24,185,438 10.6%	1,062,000 0.5%	1,568,925
13. Approval of increased placement facility Numbers of votes received Percentage of votes cast	182,075,593 79.8%	20,886,412 9.1%	24,221,108 10.6%	1,062,000 0.5%	1,627,425

*Discretionary votes in favour of the Chair of the meeting – voted for the resolution

Note: The Company currently has a total of **2,644,115,824** ordinary shares on issue and **4,763** registered shareholders.